Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.31 |
| ▸ | AURKA | O14965 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19978884 | 0.78 | PDPK1 (0.36) | PDPK1CYP1A2CYP2C19 | |
| SCHEMBL4534386 | 0.78 | PARP1 (0.35) | PDPK1PARP1PDE4BPDE4APDE4C | |
| SCHEMBL3255130 | 0.75 | PDE4A (0.51) | PDPK1PARP1PDE4BPDE4APDE4C | |
| SCHEMBL22700363 | 0.75 | MEN1 (0.37) | PDPK1CYP1A2CYP2C19 | |
| Methylguanine SCHEMBL1336757 | 0.75 | CDK1 (0.41) | PDPK1 | |
| SCHEMBL31380770 | 0.75 | XDH (0.37) | SMN1; SMN2PDPK1CYP1A2CYP2C19 | |
| SCHEMBL1443986 | 0.75 | XDH (0.37) | SMN1; SMN2PDPK1CYP1A2CYP2C19 | |
| SCHEMBL9503831 | 0.75 | PDPK1 (0.36) | PDPK1CYP1A2CYP2C19 | |
| SCHEMBL3137194 | 0.75 | PARP1 (0.32) | PARP1PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1233710 | 0.75 | PDE4A (0.38) | PDPK1PARP1PDE4BPDE4APDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325982-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN T | 2009-12-31 | — | — | US | disclosed |
| US-20080269260-A1 | PHOSPHODIESTERASE 4 INHIBITORS | HOPPER ALLEN T | 2008-10-30 | — | — | US | disclosed |
| US-7335654-B2 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORPORATION (US) | 2008-02-26 | — | — | US | disclosed |
| EP-1551837-A1 | PHOSPHODIESTERASE 4 INHIBITORS | Memory Pharmaceutical Corporation (US) | 2005-07-13 | — | — | EP | disclosed |
| US-20040102460-A1 | Phosphodiesterase 4 inhibitors | MEMORY PHARMACEUTICALS CORP. | 2004-05-27 | — | — | US | disclosed |
| WO-2004014911-A1 | PHOSPHODIESTERASE 4 INHIBITORS | MEMORY PHARMACEUTICALS CORPORATION (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269260-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | HPGD 359/4885SMN1; SMN2 2644/4885L3MBTL1 3562/4885 |
| US-20040102460-A1 | Phosphodiesterase 4 inhibitors | PDE4A, PDE3A, PDE3B | HPGD 425/4885SMN1; SMN2 2237/4885L3MBTL1 3234/4885 |
| US-20090325982-A1 | PHOSPHODIESTERASE 4 INHIBITORS | PDE4A, PDE3B, PDE3A | HPGD 359/4885SMN1; SMN2 2644/4885L3MBTL1 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.